Interventions for sexual dysfunction following treatments for cancer

Miles, Clare; Candy, Bridget; Jones, Louise; Williams, Rachael; Tookman, Adrian; King, Michael

doi:10.1002/14651858.cd005540.pub2

Cited by 69 publications

(47 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 2010 Cochrane review [31] did not find any interventions for sexual problems experienced by breast cancer patients, therefore, the search was not just limited to RCTs. Studies were included if they evaluated interventions for sexual problems experienced as a result of breast cancer diagnosis or treatment.…”

Section: Selectionmentioning

confidence: 99%

See 1 more Smart Citation

Interventions for sexual problems following treatment for breast cancer: a systematic review

Taylor

Harley

Ziegler

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

Sexual functioning is an important element of quality of life. Many women experience sexual problems as a result of a breast cancer diagnosis and its treatment. Little is known about the availability and the effectiveness of interventions for sexual problems in this patient population. Six electronic databases were searched using Medical Subject Headings and keywords. Additional hand searching of the references of relevant papers was also conducted. The searches were conducted between October 2010 and January 2011. Papers were included if they evaluated interventions for sexual problems caused as a result of breast cancer or its treatment. Studies were only included if sexual functioning was reported using a patient-reported outcome questionnaire. Studies were excluded if sexual functioning was measured but improving sexual problems was not one of the main aims of the intervention. 3514 papers were identified in the initial search. 21 papers were selected for inclusion. Studies were of mixed methodological quality; 15 randomised trials were identified, many included small sample sizes and the use of non-validated questionnaires. Three main types of interventions were identified: Exercise (2), medical (2) and psycho-educational (17). The psycho-educational interventions included skills-based training such as problem-solving and communication skills, counselling, hypnosis, education and specific sex-therapies. Interventions were delivered to individual patients, patients and their partners (couple-based) and groups of patients. The widespread methodological variability hinders the development of a coherent picture about which interventions work for whom. Tentative findings suggest the most effective interventions are couple-based psycho-educational interventions that include an element of sexual therapy. More methodologically strong research is needed before any intervention can be recommended for clinical practice. Improved screening and classification of sexual problems will ensure interventions can be more effectively targeted to suit individual patient needs.

show abstract

Section: Selectionmentioning

confidence: 99%

“…A systematic review evaluating the use of interventions for sexual dysfunction after cancer identified 11 randomised control trials (RCTs) [31]. Ten of the RCTs were conducted with prostate cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Interventions for sexual problems following treatment for breast cancer: a systematic review

Taylor

Harley

Ziegler

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Current research supports the use of oral erectile agents (phosphodiesterase type 5 (PDE5) inhibitors) to manage erectile dysfunction (ED) following radical prostatectomy [19] . Urinary incontinence (UI) ranges from 5% to over 60% [20] among men undergoing radical prostatectomy, but is a lesser problem among men undergoing radiotherapy [21] . Hormone treatments impact libido and erectile function, as well as produce many other deleterious systemic effects, but do not result in urinary adverse effects [22] .…”

Section: Discussionmentioning

confidence: 99%

Conversion from active surveillance to active treatment for prostate cancer: A qualitative analysis

Kazer

2012

JNEP

View full text Add to dashboard Cite

Active surveillance (AS) has been an option for prostate cancer management for many years. However, only about 10% of clinically appropriate prostate cancer patients undergo AS. The reasons for the low selection and adherence to AS are unknown. The purpose of this qualitative study was to examine the reasons why men convert from AS to active treatment. Known converters from AS to active treatment were identified through the PI's prior study with this population and participating urologists. A purposive sample of six participants was interviewed using a structured interview instrument developed by the researcher to examine reasons why participants converted from AS to active treatment. Participant recruitment was based out of a Urology Clinic in New Haven, Connecticut, USA. Four themes emerged from the analysis of research transcripts: 1) A Dangerous Wait, 2) Clinical Surveillance, 3) Need for Information & Support, 4) The Aftermath. The results of the study will inform health care providers regarding the education and psychosocial support needs of men undergoing AS for prostate cancer.

show abstract

“…They include age, diabetes, heart disease, chronic health conditions, urinary tract symptoms, previous hysterectomy, female genital mutilation. Overall, perceived poor health conditions are considered as predictors for women' s lack of sexual desire, arousal, orgasm and dyspareunia (7,(18)(19). -absent or decreased interest in sexual activity -absent or decreased sexual or erotic thoughts or fantasies -absent or decreased initiation of sexual activity and unreceptive to a partner's attempts to initiate -absent or decreased sexual excitement or pleasure during sexual activity in almost all or all sexual encounters -absent or decreased sexual interest or arousal in response to any internal or external sexual or erotic cues -absent or decreased genital or non-genital sensations during sexual activity in almost all or sexual encounters Female orgasmic disorder (either of the following) -marked delay in, marked infrequency of, or absence of orgasm -markedly decreased intensity of orgasmic sensations Genito-pelvic pain-penetration disorder (at least one of the following difficulties) -vaginal penetration during intercourse -marked vulvovaginal or pelvic pain during vaginal intercourse or penetration attempts -marked fear or anxiety about vulvovaginal or pelvic pain in anticipation of, during, or as a result of vaginal penetration -marked tensing or tightening of the pelvic floor muscles during attempted vaginal penetration Substance-or medication-induced sexual dysfunction -sexual dysfunction etiologically related to a medication or substance (occurs in both men and women) Other specified sexual dysfunction -other Unspecified sexual dysfunction -unspecified°…”

Section: Introductionmentioning

confidence: 99%

Tadalafil once daily: Narrative review of a treatment option for female sexual dysfunctions (FSD) in midlife and older women

Borghi

Dell’Atti²

2017

Arch Ital Urol Androl

View full text Add to dashboard Cite

Female Sexual Disorders (FSD) include a complex, multidimensional, individual experience that can change as an individual age, suggesting that these problems are caused by multiple factors including psychosocial factors, personal relationships, pathologic changes caused by diseases, and pharmacologic influences. Menopause is an important time for middle aged women and postmenopausal physiological changes could have a significant role in the development of FSD. Few is still known about their correct definition and treatment. Their incidence, prevalence and risk factors are difficult to define because of a high level of overlap in the experience of problems with desire, arousal, and orgasm. Little evidences are known about the best therapeutic approach, and both non-pharmacological and pharmacological treatment options have been described. Among these, phosphodiesterase type 5 inhibitors could be an effective option for many subtypes of female sexual disorders, with an improvement in different aspects of sexual function, such as desire, arousal, orgasm and sexual satisfaction. In this paper authors reviewed what is already known about the use of these vasoactive agents, particularly tadalafil, as a treatment option for female sexual disturbances.KEY WORDS: Female Sexual Disorders; Phosphodiesterase type 5 inhibitors; Tadalafil; Women. changes could have a significant role in the development of FSD. Nevertheless, despite an increased awareness of its pathophysiology, studies didn't find an agreement on what is the best therapeutic approach and currently there are no drugs approved for most of the complaints (3). Phosphodiesterase type 5 inhibitors (PDE5i) have been widely used for the treatment of male sexual dysfunction (4). In this paper authors review the current literature on FSD and analyse PDE5i, particularly tadalafil, as a treatment option for this health issue. CURRENT KNOWLEDGE OF FEMALE SEXUAL DYSFUNCTIONThe concept of FSD comprises a wide range of disorders, whose definition has undergone numerous changes and classifications in the past. Different definitions included hypoactive sexual desire, impaired subjective or physical genital arousal, sexual pain and inability to achieve orgasm, which are multidimensional issues, often coexisting. The most frequently used classification systems are the International Classification of Diseases, 10 th Edition (ICD-10) by the WHO (5) and the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-5) by the American Psychiatric Association (6). The former subdivides the disorders as organic or non organic. For female, organic disorders include vaginismus and dyspareunia of organic aetiology. Non organic female sexual dysfunctions include lack of sexual desire, sexual aversion or lack of sexual enjoyment, failure of genital response, orgasmic dysfunction, non-organic vaginismus, non-organic dyspareunia, excessive sexual drive and two non-specific codes. These causes are summarized in Table 1. The latter, introduced in 2013, defines the most prevalent ...

show abstract

Interventions for sexual dysfunction following treatments for cancer

Cited by 69 publications

References 140 publications

Interventions for sexual problems following treatment for breast cancer: a systematic review

Interventions for sexual problems following treatment for breast cancer: a systematic review

Conversion from active surveillance to active treatment for prostate cancer: A qualitative analysis

Tadalafil once daily: Narrative review of a treatment option for female sexual dysfunctions (FSD) in midlife and older women

Contact Info

Product

Resources

About